دورية أكاديمية
Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021
| العنوان: | Jusvinza treatment resolution in confirmed COVID-19 patients. Santiago de Cuba, 2021 |
|---|---|
| المؤلفون: | Sandra Caridad Laurencio Vallina, Martha María Arias Carbonell, Leonardo Ramos Hechavarría, Dayami Lescay Balanquet, Roger Pina Núñez |
| المصدر: | Medisur, Vol 22, Iss 1, Pp 120-126 (2024) |
| بيانات النشر: | Centro Provincial de Información de Ciencias Médicas. Cienfuegos, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Medicine (General) LCC:Public aspects of medicine |
| مصطلحات موضوعية: | infecciones por coronavirus, factores inmunitarios, morbilidad, mortalidad, resultado del tratamiento, Medicine (General), R5-920, Public aspects of medicine, RA1-1270 |
| الوصف: | Foundation: SARS-CoV-2 infection is the most important emerging disease of this century. In this context, the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) created therapeutic alternatives to combat COVID-19, including the use of Jusvinza, which is part of the protocol used in the country. Objective: to determine the Jusvinza therapeutic resolution in confirmed COVID-19 patients. Methods: a descriptive study carried out from January to September 2021, at the Dr. Joaquín Castillo Duany Military Hospital, in Santiago de Cuba. The universe consisted of 166 confirmed COVID-19 cases, to whom Jusvinza was administered. Some clinical variables (clinical status, associated non-communicable diseases, clinical progression), epidemiological (age, sex) and pharmacological (resolving, duration in days) were analyzed. A data extraction form was used, which was taken from the medical records. Results: morbidity and mortality from COVID-19 was higher in males, related to comorbidities and age over 60 years; The female sex was the one with the greatest response to treatment with Jusvinza (71.7%), which increased its percentage in the absence of associated chronic non-communicable diseases (81.4%). High-risk patients had the lowest mortality (15.8%). Conclusions: resolution in confirmed COVID-19 patients treated with Jusvinza was higher in high-risk cases than in severe and critical cases. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | Spanish; Castilian |
| تدمد: | 1727-897X |
| Relation: | http://medisur.sld.cu/index.php/medisur/article/view/45089; https://doaj.org/toc/1727-897X |
| URL الوصول: | https://doaj.org/article/f93995219a6041a2a9193939f3c95718 |
| رقم الأكسشن: | edsdoj.f93995219a6041a2a9193939f3c95718 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 1727897X |
|---|